Ahead of the American College of Rheumatology 2022 Convergence meeting on Nov. 10-14, our editorial team sat down with planning committee member Zsuzsanna McMahan, MD, MHS, of Johns Hopkins University School of Medicine, to take a deep dive into the upcoming meeting ..read more

Benjamin Nowell, PhD and Stuart Silverman, MD, FACP, FACR, discuss the recent publication of a new review article, “Cannabis for rheumatic disease pain: A review of current literature.” Investigators discovered that progress in understanding cannabis-based therapies for treating the pain associated with rheumatic disease is hindered due to a lack of standardization of clinical research and current barriers to conducting such research due to federal and state regulations. Nowell is the Director of Patient-Centered Research at CreakyJoints and principal investigator of the ArthritisPower Researc ..read more

I sat down with Dr. Benjamin Nowell and David Curtis to chat about the the recent press release that CreakyJoints published addressing updates to their ArthritisPower interface in order to improve the user’s experience, including incorporating patient perspectives. We discuss how the changes will help both patients and rheumatologists alike, recent research, and what we have to look forward to in the near future.  Dr. Nowell is Director of Patient-Centered Research at the Global Healthy Living Foundation and principal investigator of ArthritisPower and David is the Director of Technology ..read more

On this month’s episode, I spoke with Soumya D. Chakravarty, MD, PhD, to discuss the growing body of clinical evidence evaluating joint efficacy, safety and patient-reported outcomes in patients with psoriatic arthritis receiving guselkumab ..read more

Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a network meta-analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis ..read more

Louis Bessette, MD, MSc, discusses his ACR presentation, “Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial.” Bessette is affiliated with the Center for Osteoporosis and Rheumatology of Quebec. He explains why pain is a largely unmet need in this patient population, the study design, and further research his team plans on tackling in the future ..read more

On this month's episode, we interviewed Courtney Wells, PhD, MPH, MSW, to discuss the impact of COVID-19 on the quality of life of patients with rheumatic conditions, focusing on perceived risk and decision making.  ..read more

Soumya Chakravarty, MD, PhD, discusses the unmet patient needs in immune-mediated diseases as well as Janssen’s work in scientific innovation that allows patients to live their lives more unburdened by their disease. Chakravarty is the Sr Director and Strategic Lead in the Rheumatology Therapeutics area at Janssen. Time stamps:  0:45: Why do you believe fewer than 10% of patients achieve sustained clinical remission? 3:36: What are some of the unmet needs in immune-mediated diseases?  5:41: Are there any conditions that are especially suffering from this?  9:44: What are som ..read more

E Michael Lewiecki, MD, discusses “Controversies in Osteoporosis” and “What's New in Osteoporosis for 2021?” We deep dive into recent controversies and trends in osteoporosis management, predictions for 2022, and how COVID-19 had impacted the treatment landscape for rheumatologists. Time stamps: 0:52: What are some of the controversies in osteoporosis? 5:45: What is new in osteoporosis in 2021? 14:14: Have you noticed any trends in treatment over the past year? 15:32: Do you have any predictions for osteoporosis or osteoarthritis moving into 2022? 16:57: How do you personally deal with burnou ..read more

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients ..read more